Zealand Pharma Beats EPS Estimate by $1.45 in Quarterly Results

Zealand Pharma A/S reported a quarterly loss of $0.12 per share on Thursday, beating the analyst consensus estimate of a $1.57 loss by $1.45, according to Zacks. The Copenhagen-based biotechnology company paired the surprise with a return on equity of 17.56% and a net margin of 58.86%.

The print landed against a backdrop of drifting share prices. OTCMKTTS:ZLDPF shares fell $1.35 on Thursday to reach $35.50, with only 515 shares traded against an average volume of 2,350. The stock has a 12-month low of $33.08 and a 12-month high of $83.08.

What do the balance sheet numbers show?

The company's liquidity metrics stand out. Zealand Pharma carries a quick ratio of 13.98 and a current ratio of 13.98, alongside a debt-to-equity ratio of just 0.02. The market capitalization sits at $2.54 billion.

Valuation and risk measures round out the picture:

• Price-to-earnings ratio: 5.89
• Beta: 0.99
• 50-day moving average: $38.85
• 200-day moving average: $46.81

The company trades well below both moving averages, a signal that the market has been repricing the shares lower for months. In plain terms, the earnings beat did not stop the stock from falling on the day.

How are analysts responding?

Research firms split on direction this month. Wells Fargo & Company restated an "overweight" rating on shares of Zealand Pharma in a research note on Thursday, August 13th. Zacks Research lowered the company from a "strong-buy" rating to a "hold" rating in a report on Tuesday.

Barclays followed suit. The firm cut Zealand Pharma from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 8th.

The ratings distribution now skews cautious:

• One analyst rates the stock Strong Buy
• One analyst rates the stock Buy
• Nine analysts assign a Hold rating

According to data from MarketBeat, Zealand Pharma currently carries a consensus rating of "Hold" despite the earnings beat.

What does Zealand Pharma actually do?

The company, founded in 1998 and headquartered in Copenhagen, Denmark, discovers and develops peptide-based medicines with a focus on metabolic diseases and rare conditions.

Its portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines targeting obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.

The takeaway: a $1.45 EPS beat and a fortress balance sheet have not moved the analyst herd, which now leans firmly to Hold.